| Health / Medical Topics |
Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101
A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta. (NCI Thesaurus)
YOU MAY ALSO LIKE
A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the…
A substance being studied in the treatment of certain types of B-cell cancer. Epratuzumab is a monoclonal antibody that binds to a…
A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y…
A substance being studied in the treatment of some types of cancer. Yttrium Y 90-DOTA-tyr3-octreotide contains a molecule that binds to a…
A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy…
A substance being studied in the treatment of advanced pancreatic cancer. Yttrium Y 90-DOTA monoclonal antibody HuPAM4 contains a monoclonal antibody that…
